Universal Urine Drug Screening with Rapid Confirmation upon Admission to Labor and Delivery
American Journal of Perinatology · 01.08.2024 · 41 (11) · 1512-1520
DOI: 10.1055/a-2118-2841 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.08.2024. Verfasst von Lylach Haizler-Cohen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Staten Island University Hospital, Northwell Health, Staten Island, New York. Hauptthemen laut MEDLINE: Substance Abuse Detection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to describe our experience with universal urine drug screening (UDS) with rapid confirmation (RC) via liquid chromatography mass spectrometry (LC-MS) before infant's discharge, in efforts to increase detection of neonates at risk of neonatal opioid withdrawal syndrome (NOWS) while reducing patient burden related to false positive results. Study Design Two-phase retrospective study of all pregnant women admitted to our labor and delivery (L&D) unit before (phase 1, April 2018–March 2019) and after (phase 2, October 2019–September 2020) RC of UDS was initiated. Urine samples were obtained on admission and screened for drugs using an enzyme immunoassay with positive results reflexed to confirmation via LC-MS. The turnaround time for LC-MS was 1 week in phase 1 and 24 hours in phase 2. For mothers with positive LC-MS confirmation, the infant's meconium was sent for drug screening. Positive results were determined to be true or false positive based on urinary LC-MS results. The primary outcome was the rate of opioid-positive mothers who were unanticipated. The secondary outcome was the difference in rate of neonates who were observed for NOWS, before and after implementation of RC with LC-MS.
Results
In phase 2, a total of 2,395 deliveries occurred of which 2,122 (88.6%) had available UDS results. Fifty-two (2.5%) women had a positive UDS for at least one drug with LC-MS confirmation. Of those, 25 were true positive and 27 were false positive. Twenty-one (84%) true positive mothers were taking opioids and 8 (37%) of them were unanticipated positives. Among mothers with positive UDS for opioids, the neonatal observation rate for development of NOWS was 100% (22/22) and 48% (21/44) before and after implementation of LC-MS RC, respectively.
Conclusion
Universal UDS and LC-MS RC in L&D may improve detection of unanticipated positive mothers whose infants are at risk of NOWS. RC of positive results allows intervention only for confirmed cases. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Staten Island University Hospital, Northwell Health, Staten Island, New York.
- Department of Obstetrics and Gynecology, Medstar Washington Hospital Center, Washington, District of Columbia.
- Department of Pediatrics, Staten Island University Hospital, Northwell Health, Staten Island, New York.
Zitieren
APA
Haizler-Cohen, L., Collins, A., Kaplan, D. M., Giri, P., Davidov, A., Blau, J., & Fruhman, G. (2024). Universal Urine Drug Screening with Rapid Confirmation upon Admission to Labor and Delivery. American Journal of Perinatology, 41(11), 1512-1520. https://doi.org/10.1055/a-2118-2841
Vancouver
Haizler-Cohen L, Collins A, Kaplan DM, Giri P, Davidov A, Blau J, et al. Universal Urine Drug Screening with Rapid Confirmation upon Admission to Labor and Delivery. American Journal of Perinatology. 2024;41(11):1512-1520. doi:10.1055/a-2118-2841
BibTeX
@article{HaizlerCohen2024,
author = {Haizler-Cohen, Lylach and Collins, Ana and Kaplan, Dana M and Giri, Priyadarshani and Davidov, Adi and Blau, Jonathan and Fruhman, Gary},
title = {Universal Urine Drug Screening with Rapid Confirmation upon Admission to Labor and Delivery},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {11},
pages = {1512--1520},
doi = {10.1055/a-2118-2841}
}
EUVIMED